Global Patent Index - EP 3443980 A1

EP 3443980 A1 20190220 - COMPOUND FOR THE TREATMENT OF PATIENTS WITH LEPTIN-RESISTANT OBESITY, BARDET-BIEDL SYNDROME AND OTHER CILIOPATHIES

Title (en)

COMPOUND FOR THE TREATMENT OF PATIENTS WITH LEPTIN-RESISTANT OBESITY, BARDET-BIEDL SYNDROME AND OTHER CILIOPATHIES

Title (de)

VERBINDUNG ZUR BEHANDLUNG VON PATIENTEN MIT LEPTIN-RESISTENTER ADIPOSITAS, BARDET-BIEDL-SYNDROM UND ANDEREN CILIOPATHIEN

Title (fr)

COMPOSÉ POUR LE TRAITEMENT DES PATIENTS AVEC L'OBÉSITÉ RÉSISTANTE À LA LEPTINE, LE SYNDROME DE BARDET-BIEDL ET D'AUTRES CILIOPATHIES

Publication

EP 3443980 A1 20190220 (EN)

Application

EP 17186278 A 20170815

Priority

EP 17186278 A 20170815

Abstract (en)

The invention pertains to a peptide for the treatment of Bardet-Biedl syndrome and other ciliopathies, like primary ciliary dyskinesia, polycystic kidney and liver disease, nephronophthisis, Alström syndrome, Meckel-Gruber syndrome and some forms of retinal degeneration, like retinitis pigmentosa, rod-cone disease and retinal neuropathy, as well as the treatment of patients with leptin-resistant obesity.

IPC 8 full level

A61K 38/26 (2006.01); A61P 3/04 (2006.01); A61P 27/00 (2006.01); A61P 43/00 (2006.01)

CPC (source: EP)

A61K 38/26 (2013.01)

Citation (applicant)

  • EP 1012188 A1 20000628 - FORSSMANN WOLF GEORG [DE]
  • BEALES P; ELCIOGLU N; WOOLF A; PARKER D; FLINTER F: "New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey", J. MED. GENET., vol. 36, no. 6, 1 June 1999 (1999-06-01), pages 437 - 46, XP009115779, DOI: doi:10.1136/jmg.36.6.437
  • ANSLEY SJ; BADANO JL; BLACQUE OE; HILL J; HOSKINS BE; LEITCH CC; KIM JC; ROSS AJ; EICHERS ER; TESLOVICH TM: "Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl syndrome", NATURE, vol. 425, no. 6958, October 2003 (2003-10-01), pages 628 - 33, XP055072274, DOI: doi:10.1038/nature02030
  • BLACQUE OE; REARDON MJ; LI C; MCCARTHY J; MAHJOUB MR; ANSLEY SJ; BADANO JL; MAH AK; BEALES PL; DAVIDSON WS: "Loss of C. elegans BBS-7 and BBS-8 protein function results in cilia defects and compromised intraflagellar transport", GENES DEV., vol. 18, no. 13, 2004, pages 1630 - 42
  • SEDMAK T; WOLFRUM U: "Intraflagellar transport molecules in ciliary and nonciliary cells of the retina", J. CELL BIOL., vol. 189, no. 1, April 2010 (2010-04-01), pages 171 - 86
  • OROZCO, JT; WEDAMAN KP; SIGNOR D; BROWN H; ROSE L; SCHOLEY JM: "Movement of motor and cargo along cilia", NATURE, vol. 398, no. 6729, 1999, pages 674
  • BADANO JL; MITSUMA N; BEALES PL; KATSANIS N: "The ciliopathies: an emerging class of human genetic disorders", ANNU REV GENOMICS HUM GENET, vol. 7, 2006, pages 125 - 48
  • RAHMOUNI K ET AL.: "Leptin resistance contributes to obesity and hypertension in mouse models of Bardet-Biedl syndrome", J. CLIN. INVEST., vol. 118, 2008, pages 1458 - 1467
  • GUO D-F ET AL.: "The BBSome controls energy homeostasis by mediating the transport of the leptin receptor to the plasma membrane", PLOS GENETICS, vol. 12, no. 2, 29 February 2016 (2016-02-29)
  • BAGGIO LL ET AL.: "Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight", J CLIN INVEST, vol. 124, no. 10, 2014, pages 4223 - 4226
  • WILLIAMS DL ET AL.: "Leptin regulation of the anorexic response to Glucagon-like peptide-1 receptor stimulation", DIABETES, vol. 55, 2006, pages 3387 - 3393
  • MOCKEL A. ET AL.: "Pharmacological modulation of the retinal unfolded protein response in Bardet-Biedl syndrome reduces apoptosis and preserves light detection ability", J.BIOL.CHEM., vol. 287, no. 44, 2012, pages 37483 - 37494, XP009168281, DOI: doi:10.1074/jbc.M112.386821

Citation (search report)

  • [X] WO 2013124484 A1 20130829 - UNIV STRASBOURG [FR]
  • [A] WO 2017123418 A1 20170720 - SYNLOGIC INC [US]
  • [A] WO 2014131815 A1 20140904 - FUNDACIÓ HOSPITAL UNI VALL D HEBRON INST DE RECERCA [ES]
  • [A] US 2013303436 A1 20131114 - WILSON D TRAVIS [US]
  • [A] WO 9914239 A1 19990325 - FORSSMANN WOLF GEORG [DE], et al
  • [A] JOHN HARALD ET AL: "N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity", vol. 13, no. 2, 25 February 2008 (2008-02-25), pages 73 - 78, XP008146371, ISSN: 0949-2321, Retrieved from the Internet <URL:http://www.daignet.de/site-content/die-daig/fachorgan/2008/ejomr2008_vol13_2/John.pdf>

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

EP 3443980 A1 20190220

DOCDB simple family (application)

EP 17186278 A 20170815